指南与共识前列腺增生与排尿功能障碍

男性下尿路症状患者夜尿症的药物治疗:欧洲泌尿外科学会指南委员会系统综述

Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms.
指南 / 共识 · Eur Urol · 2017-06-27

该综述纳入44篇比较研究,评估男性下尿路症状相关夜尿症的药物治疗。剂量滴定的抗利尿治疗在减少夜尿次数和延长无干扰睡眠方面优于安慰剂,基线血钠是关键选择标准,需在基线、起始或滴定后及治疗期间筛查低钠血症(<130 mmol/l)。治疗下尿路功能障碍的药物短期使用通常未显著优于安慰剂。

要点

  • 剂量滴定的抗利尿治疗对夜尿次数和睡眠时长优于安慰剂。
  • 抗利尿治疗需在基线、起始或滴定后及治疗期间筛查低钠血症(<130 mmol/l)。
  • α1受体拮抗剂等下尿路药物短期使用通常未显著优于安慰剂。

核心结论

  • 剂量滴定的抗利尿治疗对夜尿症有较一致的应答,其他治疗应答不确定且临床获益可能有限。

研究设计与样本

  • 系统综述检索Embase、Medline、Cochrane系统综述和Cochrane中央数据库,无日期限制,纳入44篇比较研究。

主要发现

  • 剂量滴定的抗利尿治疗在夜尿次数和无干扰睡眠时长方面优于安慰剂,基线血钠是关键选择标准。
  • 治疗下尿路功能障碍的药物(α1受体拮抗剂、5α还原酶抑制剂、磷酸二酯酶5抑制剂、抗毒蕈碱药、β3激动剂和植物疗法)短期使用通常未显著优于安慰剂。
  • 联合治疗的获益未一致观察到。
  • 其他药物(利尿剂、助眠药、非甾体抗炎药)有时与应答或生活质量改善相关。

关键数值与推荐

  • 必须在基线、起始或剂量滴定后及治疗期间筛查低钠血症(<130 mmol/l)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验设计问题使夜尿症治疗成为具有挑战性的课题。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The treatment of nocturia is a key challenge due to the multi-factorial pathophysiology of the symptom and the disparate outcome measures used in research. OBJECTIVE: To assess and compare available therapy options for nocturia, in terms of symptom severity and quality of life. EVIDENCE ACQUISITION: Medical databases (Embase, Medline, Cochrane Systematic Reviews, Cochrane Central) were searched with no date restriction. Comparative studies were included which studied adult men with nocturia as the primary presentation and lower urinary tract symptoms including nocturia or nocturnal polyuria. Outcomes were symptom severity, quality of life, and harms. EVIDENCE SYNTHESIS: We identified 44 articles. Antidiuretic therapy using dose titration was more effective than placebo in relation to nocturnal voiding frequency and duration of undisturbed sleep; baseline serum sodium is a key selection criterion. Screening for hyponatremia (< 130 mmol/l) must be undertaken at baseline, after initiation or dose titration, and during treatment. Medications to treat lower urinary tract dysfunction (α-1 adrenergic antagonists, 5-α reductase inhibitors, phosphodiesterase type 5inhibitor, antimuscarinics, beta-3 agonist, and phytotherapy) were generally not significantly better than placebo in short-term use. Benefits with combination therapies were not consistently observed. Other medications (diuretics, agents to promote sleep, nonsteroidal anti-inflammatories) were sometimes associated with response or quality of life improvement. The recommendations of the Guideline Panel are presented. CONCLUSIONS: Issues of trial design make therapy of nocturia a challenging topic. The range of contributory factors relevant in nocturia makes it desirable to identify predictors of response to guide therapy. Consistent responses were reported for titrated antidiuretic therapy. For other therapies, responses were less certain, and potentially of limited clinical benefit. PATIENT SUMMARY: This review provides an overview of the current drug treatments of nocturia, which is the need to wake at night to pass urine. The symptom can be caused by several different medical conditions, and measuring its severity and impact varies in separate research studies. No single treatment deals with the symptom in all contexts, and careful assessment is essential to make suitable treatment selection.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sakalis VI, Karavitakis M, Bedretdinova D, et al. Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. Eur Urol. 2017. PMID: 28666669. doi:10.1016/j.eururo.2017.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。